GSK completes £8 billion Nuvalent deal as lung cancer push gathers pace

The key takeaway

GSK has completed its acquisition of Nuvalent, giving the pharmaceutical group three targeted lung cancer assets and a potentially faster route into a new area of oncology.

The transaction has an aggregate equity value of approximately $10.6 billion, equivalent to £8.0 billion. After accounting for Nuvalent's acquired cash, GSK's aggregate investment is approximately $9.4 billion, or £7.1 billion.

This is a sizeable commitment to medicines that have not yet secured approval. However, two of the acquired treatments are already under review by the US Food and Drug Administration, or FDA, with target decision dates later in 2026.

For investors, the attraction is clear: GSK is buying several targeted cancer programmes rather than relying on a single experimental treatment. The trade-off is equally clear. The acquisition price is substantial, regulatory decisions remain outstanding and the commercial opportunity has not yet been converted into approved products or disclosed revenue.

GSK's Nuvalent deal at a glance

Key detail	Figure or status
Aggregate equity value	Approximately $10.6 billion (£8.0 billion)
Investment net of cash acquired	Approximately $9.4 billion (£7.1 billion)
Lung cancer assets acquired	Three
Assets under FDA review	Two
Expected launch timing if approved	2026
Third asset's development stage	Phase I

GSK completed a tender offer for all outstanding Nuvalent shares. The announcement did not disclose the deal's expected impact on earnings, cash flow or debt, nor did it provide cost or revenue synergy targets.

What GSK is buying

Nuvalent is a Boston-based clinical-stage biopharmaceutical company focused on precisely targeted oncology therapies. These treatments are designed for cancers carrying particular genetic alterations.

The acquisition brings three non-small cell lung cancer, or NSCLC, assets into GSK's portfolio.

Zidesamtinib

Zidesamtinib, also known as NVL-520, is under FDA review for ROS1-positive NSCLC. GSK considers it a potential best-in-class asset based on clinical data.

It has received FDA Breakthrough Therapy and Orphan Drug Designations. Breakthrough Therapy designation is intended for medicines targeting serious conditions where preliminary clinical evidence indicates potential improvement over available treatment. An Orphan Drug Designation applies to treatments for rare diseases or conditions.

Neladalkib

Neladalkib, or NVL-655, is under FDA review for ALK-altered NSCLC. Like zidesamtinib, GSK describes it as a potential best-in-class asset based on clinical data.

It has also received Breakthrough Therapy and Orphan Drug Designations from the FDA.

If approved, GSK expects zidesamtinib and neladalkib to launch during 2026. The company believes the two assets have multi-blockbuster potential, although the announcement did not provide individual sales forecasts or explain the expected timing for reaching that scale.

NVL-330

The third asset, NVL-330, is being developed for HER2-altered NSCLC. It remains in phase I development, an early stage of clinical testing, making it a longer-term and less advanced part of the acquired pipeline.

Why lung cancer matters to GSK's strategy

The deal accelerates GSK's expansion beyond its existing focus on blood and women's cancers. The company wants to build a broader presence in lung cancer, gastrointestinal cancers and other solid tumours.

Chief executive Luke Miels said the completion accelerates GSK's entry into lung cancer through zidesamtinib and neladalkib. He also linked the acquired assets with Ris-Rez, GSK's B7-H3-targeted antibody-drug conjugate in phase III development.

An antibody-drug conjugate, or ADC, combines an antibody that seeks out a target on cancer cells with a drug designed to kill those cells. GSK believes the combination of Nuvalent's targeted medicines and its existing development platform could support faster expansion in lung cancer.

NSCLC is the most common form of lung cancer and can be driven by alterations involving genes such as ALK, ROS1 and HER2. It can spread to the central nervous system, while existing treatments may face mutation resistance and side effects that affect patients' quality of life.

Nuvalent's approach is intended to overcome resistance, reduce adverse events, address brain metastases and produce more durable responses. These remain development aims rather than guaranteed outcomes.

The potential positives for GSK investors

The most immediate positive is that completion removes the remaining transaction uncertainty. Nuvalent and its pipeline are now part of GSK.

Two lead assets are already at the regulatory review stage, which could make this a faster strategic addition than acquiring a business whose entire pipeline is in early development. Both FDA target decision dates are due later in 2026, and GSK expects launches in the same year if approvals are secured.

The acquisition also offers multiple shots on goal. GSK gains two advanced programmes aimed at separate genetic forms of NSCLC, plus an earlier-stage HER2-altered candidate.

Finally, the deal fits GSK's stated approach of acquiring validated assets that aim to improve the standard of care. Management sees a clear need among defined patient populations, particularly where resistance, side effects and central nervous system spread limit current treatment options.

The risks investors should watch

The largest risk is regulatory. Zidesamtinib and neladalkib remain under FDA review, so approval is not guaranteed. Any delay, rejection or restrictive product label could affect the planned 2026 launches and the acquisition's commercial case.

Clinical risk also remains. NVL-330 is only in phase I development, while even advanced medicines can face setbacks as evidence develops or after launch.

There is also a valuation and execution question. GSK is investing approximately £7.1 billion net of acquired cash before the two leading products have been approved. Management's multi-blockbuster description signals high expectations, but the announcement does not disclose forecast sales, expected profitability, integration costs or the financial returns required to justify the purchase.

Commercial execution will matter if approvals arrive. GSK will need to launch into precisely defined patient groups and establish how the medicines improve treatment compared with existing options. Details of pricing, market access and expected patient numbers were not disclosed.

What happens next?

Attention now turns to the FDA's decisions on zidesamtinib and neladalkib later in 2026. Approval would allow GSK to pursue its planned launches and begin testing the commercial logic behind the acquisition.

Investors should look for details on product labels, launch timing and any future financial guidance attached to the medicines. Progress from NVL-330 and the interaction between the Nuvalent portfolio and GSK's wider oncology pipeline will also be important.

This deal gives GSK a meaningful platform in genetically targeted lung cancer, but completion is the start of the investment case rather than the finish. The next regulatory decisions will determine whether the acquired science can begin turning into approved products and, eventually, financial returns.